An eHealth decision‐support tool to prioritize referral practices for genetic evaluation of patients with Wilms tumor

Over 10% of children with Wilms tumor (WT) have an underlying cancer predisposition syndrome (CPS). Cognizant of increasing demand for genetic evaluation and limited resources across health care settings, there is an urgent need to rationalize genetic referrals for this population. The McGill Interactive Pediatric OncoGenetic Guidelines study, a Canadian multi‐institutional initiative, aims to develop an eHealth tool to assist physicians in identifying children at elevated risk of having a CPS. As part of this project, a decisional algorithm specific to WT consisting of five tumor‐specific criteria (age <2 years, bilaterality/multifocality, stromal‐predominant histology, nephrogenic rests, and overgrowth features) and universal criteria including features of family history suspicious for CPS and congenital anomalies, was developed. Application of the algorithm generates a binary recommendation—for or against genetic referral for CPS evaluation. To evaluate the algorithm's sensitivity for CPS identification, we retrospectively applied the tool in consecutive pediatric patients (n = 180) with WT, diagnosed and/or treated at The Hospital for Sick Children (1997–2016). Odds ratios were calculated to evaluate the strengths of associations between each criterion and specific CPS subtypes. Application of the algorithm identified 100% of children with WT and a confirmed CPS (n = 27). Age <2 years, bilaterality/multifocality, and congenital anomalies were strongly associated with pathogenic variants in WT1. Presence of >1 overgrowth feature was strongly associated with Beckwith‐Wiedemann syndrome. Stromal‐predominant histology did not contribute to CPS identification. We recommend the incorporation of the WT algorithm in the routine assessment of children with WT to facilitate prioritization of genetic referrals in a sustainable manner.

[1]  S. Seal,et al.  Identification of new Wilms tumour predisposition genes: an exome sequencing study , 2019, The Lancet. Child & adolescent health.

[2]  M. Gessler,et al.  TRIM28 haploinsufficiency predisposes to Wilms tumor , 2019, International journal of cancer.

[3]  R. Hennekam,et al.  Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement , 2018, Nature Reviews Endocrinology.

[4]  W. Foulkes,et al.  The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation , 2017, Pediatric blood & cancer.

[5]  J. Mulliken,et al.  Sonographic screening for Wilms tumor in children with CLOVES syndrome , 2017, Pediatric blood & cancer.

[6]  C. Shaw,et al.  Mutations in the transcriptional repressor REST predispose to Wilms tumor , 2015, Nature Genetics.

[7]  J. Soulier,et al.  Fanconi anemia and solid malignancies in childhood: A national retrospective study , 2015, Pediatric blood & cancer.

[8]  S. Seal,et al.  Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour , 2014, Nature Communications.

[9]  H. Brisse,et al.  Malformations, genetic abnormalities, and wilms tumor , 2014, Pediatric blood & cancer.

[10]  R. Pieters,et al.  Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients. , 2012, European journal of cancer.

[11]  J. Opitz,et al.  Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility , 2012, Nature Genetics.

[12]  W. Foulkes,et al.  Extending the phenotypes associated with DICER1 mutations , 2011, Human mutation.

[13]  N. Breslow,et al.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor. , 2011, The Journal of urology.

[14]  James R. Anderson,et al.  The Management of Synchronous Bilateral Wilms Tumor: A Report from the National Wilms Tumor Study Group , 2011, Annals of surgery.

[15]  E. Denamur,et al.  Management of Wilms tumors in Drash and Frasier syndromes , 2009, Pediatric blood & cancer.

[16]  N. Breslow,et al.  Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor , 2006, Pediatric blood & cancer.

[17]  N. Rahman,et al.  Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour , 2006, Journal of Medical Genetics.

[18]  Bernard V Fischbach,et al.  WAGR Syndrome: A Clinical Review of 54 Cases , 2005, Pediatrics.

[19]  N. Rahman,et al.  Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Huff,et al.  Twenty‐four new cases of WT1 germline mutations and review of the literature: Genotype/phenotype correlations for Wilms tumor development , 2004, American journal of medical genetics. Part A.

[21]  A. Kelsey,et al.  The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study , 2000, British Journal of Cancer.

[22]  S. Schneider,et al.  Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  N Breslow,et al.  Epidemiology of Wilms tumor. , 1993, Medical and pediatric oncology.